Table 3: Global symptom improvement, CHM versus placebo.

TherapyStudyResponse rate, % (response/)Therapeutic gain, %NNTRR (95% CI)
CHMPlacebo

IndividualizedBensoussan et al. 1998 [27]47.4 (18/38)29.4 (5/17)18.05.61.61 (0.72, 3.62)
SLIS65.2 (152/233)46.9 (97/207)18.35.51.42 (1.08, 1.86)
Bensoussan et al. 1998 [27]67.4 (29/43)33.3 (6/18)34.12.92.02 (1.02, 4.02)
Leung et al. 2006 [18]35.0 (21/60)44.1 (26/59)−9.10.79 (0.51, 1.24)
Li et al. 2010 [33]83.3 (25/30)60.0 (18/30)23.34.31.39 (1.00, 1.94)
Li et al. 2014 [40]72.5 (58/80)45.0 (36/80)27.53.61.61 (1.22, 2.13)
Luo 2002 [28]95.0 (19/20)55.0 (11/20)40.02.51.73 (1.15, 2.60)
WKIS90.0 (144/160)43.8 (70/160)46.22.22.06 (1.71, 2.47)
Li 2011 [36]92.5 (37/40)42.5 (17/40)50.022.18 (1.50, 3.15)
Su et al. 2013 [37]89.2 (107/120)44.2 (53/120)45.02.22.02 (1.64, 2.49)

Total72.9 (314/431)44.8 (172/384)28.13.61.62 (1.31, 2.49)

CHM, Chinese herbal medicine; NNT, number needed to treat; RR, relative risk; SLIS, soothing the liver and invigorating the spleen; WKIS, warming the kidney and invigorating the spleen; I, individualized group; S, standard group.